Overproduction of corticotropin by the pituitary gland or extrapituitary tumors leads to hypercortisolism or Cushing syndrome. Diagnosis of suspected Cushing syndrome involves 3 major steps: confirmation of hypercortisolism, differentiation between corticotropin-independent and corticotropin-dependent causes of Cushing syndrome, and distinction...
-
2014 (v1)PublicationUploaded on: April 14, 2023
-
2015 (v1)Publication
Neuroendocrine tumors (NETs) produce various hormones and bioactive substances and are known to express a large variety of peptide hormone receptors. While these hormones and receptors play a role in the pathophysiology of this heterogeneous group of tumors, they also form an important target for treatment and diagnosis. One of the most...
Uploaded on: March 27, 2023 -
2013 (v1)Publication
The actions of somatostatin (SRIF) are mediated by specific G protein-coupled receptors, named SRIF receptor (SSTR) subtypes 1, 2, 3 and 5. SRIF binding to SSTR activates a series of second messenger systems, resulting in the inhibition of calcium channels and adenylate cyclase activity, ultimately leading to inhibition of hormone secretion,...
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms with heterogeneous clinical behavior and potential long-term survival. In 2006/2007, the European Neuroendocrine Tumors Society introduced an important parameter, grade (based on mitoses and Ki-67 proliferation rate), which became part of the latest 2010-WHO...
Uploaded on: April 14, 2023 -
2014 (v1)Publication
Neuroendocrine tumors (NETs) are heterogeneous neoplasms with respect to molecular characteristics and clinical outcome. Although slow-growing, NETs are often late diagnosed, already showing invasion of adjacent tissues and metastases. Precise knowledge of NET biological and molecular features has opened the door to the identification of novel...
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Background/Aim: The neuroendocrine tumor (NET) proliferation-based grading system (ENETS/WHO) for gastroenteropancreatic (GEP) tumors has proved reliable for prognostic stratification. To date, concerns exist regarding Ki-67 heterogeneity within the tumor and little is known on whether grade varies between primary and secondary sites. As tumor...
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Preclinical research on neuroendocrine tumors usually involves immortalized cell lines and few animal models. In the present study we described an in vivo model based on patient-derived xenografts of neuroendocrine tumor cells in zebrafish (Danio rerio) embryos, allowing a rapid analysis of the angiogenic and invasive potential. Patient-derived...
Uploaded on: April 14, 2023 -
2014 (v1)Publication
Chemokines are chemotactic regulators of immune surveillance in physiological and pathological conditions such as inflammation, infection, and cancer. Several chemokines and cognate receptors are constitutively expressed in the central nervous system, not only in glial and endothelial cells but also in neurons, controlling neurogenesis, neurite...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
Diabetes insipidus is a disease in which large volumes of dilute urine (polyuria) are excreted due to vasopressin (AVP) deficiency [central diabetes insipidus (CDI)] or to AVP resistance (nephrogenic diabetes insipidus). In the majority of patients, the occurrence of CDI is related to the destruction or degeneration of neurons of the...
Uploaded on: March 27, 2023 -
2017 (v1)Publication
Therapeutic management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is challenging. The mammalian target of rapamycin (mTOR) inhibitor everolimus recently obtained approval from the Food and Drug Administration for the treatment of patients with advanced pancreatic neuroendocrine tumors (pNETs). Despite its promising antitumor...
Uploaded on: April 14, 2023